Cancer Antigen (CA) 27.29
Also known as: CA 27.29 Antigen, Truquant BR
Use
Manage patients with metastatic carcinoma of the breast
Special Instructions
Not provided.
Limitations
This test quantifies CA 27.29 antigen levels in the serum of patients previously treated for stage II or stage III breast cancer. It should be used alongside other clinical methods for early detection of recurrence. An elevated CA 27.29 level in patients in remission of stage II or III breast cancer can indicate a high probability of recurrence.
Methodology
Immunoassay (Immunochemiluminometric assay (ICMA))
Biomarkers
CA 27.29
Protein
LOINC Codes
- 17842-6 - Cancer Ag27-29 SerPl-aCnc
- 17842-6 - Cancer Ag27-29 SerPl-aCnc
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Storage Instructions
Refrigerate.
Causes for Rejection
Plasma other than EDTA plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |
| Frozen | >1 month |
Other tests from different labs that may be relevant